| Bioactivity | RGX-104 is an orally bioavailable and potent liver-X nuclear hormone receptor (LXR) agonist that modulates innate immunity via transcriptional activation of the ApoE gene. |
| Target | LXR |
| In Vivo | Oral administration of RGX-104 (100 mg/kg, daily) to animals bearing palpable tumors significantly suppresses the growth of multiple cancer types. Co-administration of RGX-104 with anti-PD-1 is superior to administration of either RGX-104 or anti-PD-1 alone. Importantly, co-administration of RGX-104 with anti-PD-1 therapy is well tolerated by mice, with no overt signs of toxicity[1]. Animal Model: |
| Name | RGX-104 |
| CAS | 610318-54-2 |
| Formula | C34H33ClF3NO3 |
| Molar Mass | 596.08 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
| Reference | [1]. Tavazoie MF, et al. LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer. Cell. 2018 Feb 8;172(4):825-840.e18. |
RGX-104
CAS: 610318-54-2 F: C34H33ClF3NO3 W: 596.08
RGX-104 is an orally bioavailable and potent liver-X nuclear hormone receptor (LXR) agonist that modulates innate immuni
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.